Hims & Hers Health Inc., the telehealth company that built a billion-dollar business by democratizing access to treatments for hair loss, erectile dysfunction, and mental health, has abruptly halted sales of a weight-loss pill after facing threats of legal action. The move represents a significant inflection point for a company that had aggressively positioned itself as a disruptor in the booming GLP-1 weight-loss market — and raises broader questions about the boundaries telehealth companies face when they venture into pharmaceutical territory dominated by some of the world’s most powerful drugmakers.
The decision to pull the product came after the company received legal threats related to the formulation and marketing of the pill, according to reporting by CNBC. While the specific parties behind the legal pressure have not been fully disclosed, the action underscores the increasingly contentious battle between telehealth platforms offering compounded or alternative weight-loss treatments and the established pharmaceutical giants that hold patents on blockbuster GLP-1 receptor agonist drugs like Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Mounjaro and Zepbound.
A High-Stakes Gamble on Weight Loss That Defined Hims & Hers’ Growth Story
Hims & Hers had made weight loss a central pillar of its growth strategy in recent years, capitalizing on the unprecedented consumer demand for GLP-1 medications that has reshaped the healthcare industry. The company had previously offered compounded semaglutide — the active ingredient in Novo Nordisk’s Wegovy and Ozempic — through its platform during a period when the FDA had placed those branded drugs on its shortage list. That shortage designation allowed compounding pharmacies to legally produce copies of the medications, and Hims & Hers seized the opportunity to offer them at significantly lower prices than the branded versions, which can cost more than $1,000 per month without insurance.
The weight-loss category quickly became a revenue engine for the company. Hims & Hers reported explosive growth in its subscriber base, with weight-loss customers contributing meaningfully to the company’s top line. The stock price surged as investors bet that the company could carve out a durable position in the weight-loss market. But that optimism was always tempered by a fundamental risk: the compounded semaglutide business depended on the FDA’s shortage designation, and once Novo Nordisk ramped up production sufficiently, that designation could be — and eventually was — lifted.
The FDA Shortage Resolution That Changed Everything
When the FDA resolved the semaglutide shortage in early 2025, it sent shockwaves through the compounding industry and through Hims & Hers’ stock price. The resolution meant that compounding pharmacies no longer had the legal cover to produce copies of semaglutide, and Novo Nordisk moved aggressively to protect its intellectual property and market share. Hims & Hers was forced to wind down its compounded semaglutide offerings, a move that threatened to unravel one of the most compelling growth narratives in telehealth.
In response, the company pivoted. Rather than exit the weight-loss market entirely, Hims & Hers began developing and marketing alternative weight-loss products, including oral formulations that it positioned as accessible, affordable options for consumers who could not obtain or afford branded GLP-1 medications. The weight-loss pill that the company has now pulled was part of this pivot — an attempt to maintain its foothold in the category without relying on compounded versions of patented drugs. But the legal threats suggest that even this alternative approach has run into formidable opposition.
Legal Pressure Mounts as Big Pharma Guards Its Territory
The pharmaceutical industry has watched the rise of telehealth-driven weight-loss treatments with growing alarm. Novo Nordisk and Eli Lilly, which together dominate the GLP-1 market, have invested billions in research, development, clinical trials, and manufacturing capacity to bring their drugs to market. They have shown little tolerance for companies they view as free-riding on their innovations or potentially confusing consumers about the nature and safety of alternative products.
Novo Nordisk, in particular, has been aggressive in pursuing legal action against compounding pharmacies and telehealth platforms. The Danish pharmaceutical giant has filed lawsuits and sent cease-and-desist letters to numerous entities it accuses of infringing on its patents or misleading consumers. Eli Lilly has taken similar steps to protect its franchise. The legal threats directed at Hims & Hers appear to be part of this broader enforcement campaign, though the specific legal theories — whether patent infringement, trademark concerns, or regulatory compliance issues — have not been fully detailed in public filings.
What the Pill Pullback Means for Hims & Hers’ Financial Outlook
For investors, the decision to stop offering the weight-loss pill raises urgent questions about the durability of Hims & Hers’ revenue model. The company’s stock had already experienced significant volatility tied to its weight-loss business, and this latest setback could further erode confidence in the company’s ability to sustain growth in the category. Wall Street analysts have been divided on the stock, with bulls arguing that the company’s diversified platform — spanning dermatology, sexual health, mental health, and primary care — provides a solid foundation regardless of what happens with weight loss, and bears contending that the weight-loss narrative was the primary driver of the stock’s premium valuation.
The company’s management has sought to reassure investors that weight loss remains a strategic priority, even as the specific products and approaches may evolve. Hims & Hers CEO Andrew Dudum has consistently emphasized the company’s mission to make healthcare more accessible and affordable, and has framed the weight-loss category as one where enormous unmet demand exists. But the gap between that vision and the legal and regulatory realities of the pharmaceutical industry has proven difficult to bridge.
The Broader Telehealth Industry Faces a Reckoning
Hims & Hers is not alone in facing these challenges. The entire telehealth sector has grappled with the tension between consumer demand for affordable weight-loss treatments and the legal protections afforded to branded pharmaceutical products. Companies like Ro, Noom, and numerous smaller telehealth startups have also sought to capitalize on the GLP-1 boom, and many have encountered similar legal and regulatory headwinds. The FDA’s evolving stance on compounded medications, combined with aggressive enforcement by brand-name drugmakers, has created an environment of significant uncertainty for any company operating in this space.
Consumer advocacy groups have argued that the aggressive legal tactics employed by pharmaceutical companies are ultimately harmful to patients, many of whom cannot afford the branded medications and have benefited from lower-cost alternatives. The debate touches on fundamental questions about drug pricing, patent law, and the role of compounding pharmacies in the American healthcare system — questions that are unlikely to be resolved quickly or cleanly.
Regulatory and Political Crosscurrents Add Complexity
The political environment adds another layer of uncertainty. The Trump administration has signaled interest in lowering drug prices and increasing competition in the pharmaceutical industry, but it has also taken steps that some interpret as favorable to established drugmakers. The FDA’s handling of the semaglutide shortage and its aftermath has been closely watched by lawmakers on both sides of the aisle, with some members of Congress calling for greater access to compounded medications and others emphasizing the importance of safety and regulatory oversight.
For Hims & Hers, navigating these crosscurrents requires a delicate balance. The company must find ways to serve the enormous consumer demand for weight-loss solutions while staying within the bounds of an increasingly aggressive legal and regulatory framework. The decision to pull the weight-loss pill, while painful in the short term, may reflect a pragmatic calculation that the legal risks of continuing to offer the product outweighed the commercial benefits.
What Comes Next for the Telehealth Disruptor
Looking ahead, Hims & Hers faces a critical strategic question: how to remain relevant in the weight-loss market without running afoul of the legal and regulatory constraints that have already forced it to retreat twice — first from compounded semaglutide, and now from its alternative oral formulation. The company has several potential paths forward, including partnering with branded drugmakers to offer their products through its platform, developing novel formulations that do not implicate existing patents, or shifting its weight-loss strategy toward behavioral and nutritional approaches that complement rather than compete with pharmaceutical treatments.
The stakes are enormous. The global market for GLP-1 medications is projected to exceed $100 billion by the end of the decade, and the consumer appetite for weight-loss solutions shows no signs of abating. Hims & Hers has demonstrated an ability to build a loyal customer base and a powerful brand in telehealth. Whether it can translate those assets into a sustainable weight-loss business — one that withstands the legal firepower of some of the world’s largest pharmaceutical companies — will be one of the defining questions for the company and the broader telehealth industry in the years ahead. As reported by CNBC, the company’s decision to halt the pill marks not an ending, but the beginning of a new and uncertain chapter in the collision between telehealth innovation and pharmaceutical incumbency.
WebProNews is an iEntry Publication